These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Reed GL; Houng AK Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598 [TBL] [Abstract][Full Text] [Related]
3. Inactivation of purified human alpha 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents. Miles LA; Burnier JP; Verlander MS; Goodman M; Kleiss AJ; Griffin JH Blood; 1981 Jun; 57(6):1015-24. PubMed ID: 6452920 [TBL] [Abstract][Full Text] [Related]
4. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Agren A; Jörneskog G; Elgue G; Henriksson P; Wallen H; Wiman B Diabetes Care; 2014 Jul; 37(7):2007-14. PubMed ID: 24760258 [TBL] [Abstract][Full Text] [Related]
5. [Profibrinolytic activity of recombinant hirudin?]. Tsakiris DA; Meyer D; Fabbri J; Close P; Marbet GA Schweiz Med Wochenschr; 1991 Mar; 121(10):338-40. PubMed ID: 2028237 [TBL] [Abstract][Full Text] [Related]
6. Effect of a synthetic carboxy-terminal peptide of alpha(2)-antiplasmin on urokinase-induced fibrinolysis. Lee KN; Jackson KW; McKee PA Thromb Res; 2002 Feb; 105(3):263-70. PubMed ID: 11927133 [TBL] [Abstract][Full Text] [Related]
7. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation. Singh S; Houng A; Reed GL Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005 [TBL] [Abstract][Full Text] [Related]
8. Plasminogen binding by alpha 2-antiplasmin and histidine-rich glycoprotein does not inhibit plasminogen activation at the surface of fibrin. Angles-Cano E; Rouy D; Lijnen HR Biochim Biophys Acta; 1992 Dec; 1156(1):34-42. PubMed ID: 1472536 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. Collen D; Van Hoef B; Schlott B; Hartmann M; Gührs KH; Lijnen HR Eur J Biochem; 1993 Aug; 216(1):307-14. PubMed ID: 7689966 [TBL] [Abstract][Full Text] [Related]
10. Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy. Goto S; Kawai Y; Handa S; Takahashi E; Ogawa S; Watanabe K; Hori S; Ikeda Y Cardiology; 1993; 82(4):274-9. PubMed ID: 8402754 [TBL] [Abstract][Full Text] [Related]
11. Protein C and fibrinolysis: a link between coagulation and fibrinolysis. de Fouw NJ; Haverkate F; Bertina RM Adv Exp Med Biol; 1990; 281():235-43. PubMed ID: 2102614 [TBL] [Abstract][Full Text] [Related]
12. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Leebeek FW; Kluft C; Knot EA; de Maat MP; Wilson JH Gastroenterology; 1991 Nov; 101(5):1382-90. PubMed ID: 1718809 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Matsuo O; Rijken DC; Collen D Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339 [TBL] [Abstract][Full Text] [Related]
14. [Heparin effect on hydrolysis of fibrin clots in a bull and a man with varying fibrinolytic systems]. Makogonenko EM Ukr Biokhim Zh (1978); 1997; 69(5-6):109-16. PubMed ID: 9606832 [TBL] [Abstract][Full Text] [Related]
15. Effects of pro-urokinase and urokinase on the fibrinolytic system in man. Trübestein G; Popov S; Wolf H; Welzel D Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078 [TBL] [Abstract][Full Text] [Related]